Innovent preps for Chinese filing after picankibart shines in psoriasis study

28 May 2024
firstwordpharma.com
Clinical ResultPhase 3Phase 2
Innovent Biologics will seek approval in China for its psoriasis candidate picankibart (IBI112) following positive findings from a registrational study. The anti-IL-23p19 antibody met the primary and key secondary endpoints of the Phase III CLEAR-1 study in Chinese patients with moderate-to-severe plaque psoriasis.
The trial enrolled 500 patients who were randomly assigned to either placebo or picankibart 200mg every four weeks at week 0, 4 and 8 followed by 200mg or 100mg every 12 weeks. Co-primary endpoints included the proportion of participants achieving a ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) and those attaining a static Physician's Global Assessment (sPGA) score of clear (0) or almost clear (1) at week 16.
Efficacy onset and maintenance
Results announced Monday showed that 80.3% of picankibart-treated participants achieved PASI 90 and 93.5% achieved sPGA 0 or 1 at week 16, significantly higher than the 2.0% and 13.1% of those receiving placebo, respectively. Moreover, the company also noted sustained skin clearance for picankibart, with 84.9% and 85.9% of participants on the 200mg dose every 12 weeks achieving PASI 90 and sPGA 0 or 1, respectively, at the one-year mark.
Principal investigator Yulin Shi highlighted picankibart’s “short-term onset and long-term maintenance of efficacy,” alongside improved “convenience and adherence” offered by the every-12-week dosing regimen.
Picankibart also demonstrated superiority over placebo on key secondary endpoints, including other measures of psoriasis severity and quality of life. The antibody showed a favourable safety profile as well, with no new safety signals identified.
“There is no IL-23p19 target drug independently developed by Chinese enterprises in the domestic market,” remarked Lei Qian, vice president of clinical development at Innovent, adding that picankibart administered five or six times a year could offer “convenience value as a new treatment option compared to the current…drugs (7-16 times per year).”
Other biologics targeting IL-23p19 in moderate-to-severe plaque psoriasis include Johnson & Johnson’s Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab), and AbbVie’s Skyrizi (risankizumab).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.